Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study
- 1 August 2003
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 38 (2), 493-502
- https://doi.org/10.1053/jhep.2003.50329
Abstract
The prognosis of patients with chronic hepatitis C after interferon (IFN) therapy is still poorly defined. The present study evaluated the effect of IFN therapy on survival in a cohort of such patients. The study included 459 patients with biopsy-proven C-viral chronic liver disease who were followed for 8.2 +/- 2.9 years (range, 7-183 months). Survival status was examined by medical records or direct questionnaires. Fifteen (14%) of 104 IFN-untreated patients and 33 (9%) of 355 patients treated with IFN died during follow-up. Among the treated patients, 4 (3%) of 116 with sustained virologic response and 29 (12%) of 239 without sustained virologic response died. Liver-related death was shown in 32 (67%) patients, and hepatocellular carcinoma (HCC) caused 25 (52%) of the 48 deaths. Multivariate Cox proportional regression analysis revealed that IFN treatment decreased the risk ratio for overall death to 0.521 (confidence interval [CI]: 0.263-1.034) and for liver-related death to 0.208 (CI: 0.088-0.495) compared with untreated patients, and sustained virologic response showed a decrease in the risk ratio for overall death to 0.219 (CI: 0.068-0.710) and for liver-related death to 0.030 (CI: 0.003-0.267). IFN treatment showed no association with liver-unrelated death. Furthermore, the standardized mortality ratios for all causes of death and liver-related death were reduced in IFN-treated patients compared with untreated patients (1.4 vs. 2.0 for total death and 7.9 vs. 19.7 for liver-related death). In conclusion, the present data suggest that IFN therapy has a long-term clinical benefit for patients with chronic hepatitis C patients by reducing liver-related death, especially in patients with sustained virologic response.Keywords
This publication has 31 references indexed in Scilit:
- Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approachJournal of Hepatology, 2001
- Treatment of hepatitis C virus-related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatmentHepatology, 1999
- Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type CJournal of Hepatology, 1997
- Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfaHepatology, 1996
- Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosisJournal of Hepatology, 1996
- Classification of chronic hepatitis: Diagnosis, grading and stagingHepatology, 1994
- Significance of specific antibody assay for genotyping of hepatitis C virusHepatology, 1994
- High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α2b for 60 weeksHepatology, 1994
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989
- PREVALENCE OF ANTIBODIES TO HEPATITIS C VIRUS IN SPANISH PATIENTS WITH HEPATOCELLULAR CARCINOMA AND HEPATIC CIRRHOSISThe Lancet, 1989